Anti-Hu CD138 Pacific Orange™

Anti-Hu CD138 Pacific Orange™
Regulatory status
RUO
Antigen
CD138
Clone
MI15
Format
Pacific Orange™
Reactivity
Rat, Human, Non-human primates
Application
FC (QC tested)
Excitation laser
violet (405 nm)
Variant
100 tests
PO-814-T100
In stock
Variant
0.1 mg
11-261-C100
In stock
Product details
Images
References
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody MI15 recognizes CD138 (syndecan 1), a 65-70 kDa heparan sulfate proteoglycan expressed mainly in the epidermis and plasma cells, but also in growth factor-stimulated lymphocytes.
Application
FC (QC tested)
Application details
Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Reactivity
Rat, Human, Non-human primates
Immunogen
A mixture of U266 and XG-1 human myeloma cell lines
Other names
syndecan 1, SYND1, SDC
Preparation
The purified antibody is conjugated with Pacific Orange™ under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.
Licence note
Alexa Fluor®, Pacific Blue™ and Pacific Orange™ are registered trademarks of Life Technologies Corporation.
Licence label
This product is provided under an agreement between Molecular Probes, Inc. (a wholly owned subsidiary of Invitrogen Corporation), and Exbio Praha, a.s., and the manufacture, use, sale or import of this product may be subject to one or more U.S. patents, pending applications, and corresponding non-U.S. equivalents, owned by Molecular Probes, Inc. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity), including use in flow cytometry that does not utilize a bead based array, but excluding use in combination with microarrays or High Content Screening. The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Molecular Probes, Inc., Business Development, 29851 Willow Creek Road, Eugene, OR 97402, USA, Tel: (541) 465-8300. Fax: (541) 335-0504.
PO-814 FC DotPlot
Flow cytometry multicolor surface staining of human bone marrow mononuclear cells from human bone marrow of a patient with multiple myeloma using anti-human CD38 (HIT2) FITC and anti-human CD138 (MI15) Pacific Orange™.
PO-814 FC Histogram
Separation of anti-human CD138 positive plasma cells (red-filled) from anti-human CD138 negative neutrophil granulocytes (black-dashed) in flow cytometry analysis (surface staining) of human bone marrow of a patient with multiple myeloma stained using anti-human CD138 (MI15) Pacific Orange™.

General references:

Hayashida K, Johnston DR, Goldberger O, Park PW: Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway. J Biol Chem. 2006 Aug 25;281(34):24365-74.
PubMed
Choi DS, Kim JH, Ryu HS, Kim HC, Han JH, Lee JS, Min CK: Syndecan-1, a key regulator of cell viability in endometrial cancer. Int J Cancer. 2007 Aug 15;121(4):741-50.
PubMed
Manakil JF, Seymour GJ, Bartold PM: Effect of cytokine and antigen stimulation on peripheral blood lymphocyte syndecan-1 expression. Oral Microbiol Immunol. 2007 Aug;22(4):272-6.
PubMed
Muto T, Miyoshi K, Munesue S, Nakada H, Okayama M, Matsuo T, Noma T: Differential expression of syndecan isoforms during mouse incisor amelogenesis. J Med Invest. 2007 Aug;54(3-4):331-9.
PubMed
Ojeh N, Hiilesvuo K, Wärri A, Salmivirta M, Henttinen T, Määttä A: Ectopic expression of syndecan-1 in basal epidermis affects keratinocyte proliferation and wound re-epithelialization. J Invest Dermatol. 2008 Jan;128(1):26-34.
PubMed
Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M: Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2008 Jan 7.
PubMed

Product specific references:

Nadalin MR, Fregnani ER, Silva-Sousa YT, Perez DE: Syndecan-1 (CD138) and Ki-67 expression in odontogenic cystic lesions. Braz Dent J. 2011;22(3):223-9.
PubMed
Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Rème T, Bolloré K, Vendrell JP, Le Gallou S, Mourcin F, De Vos J, Kassambara A, Duperray C, Hose D, Fest T, Tarte K, Klein B: Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol. 2011 Oct 15;187(8):3931-41.
PubMed
Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, Kok CH, Zannettino AC: PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol. 2015 Oct 6;8:106.
PubMed
Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kröger N: Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst. 2012 Jul 3;104(13):1005-20.
PubMed
Krishnan SR, Luk F, Brown RD, Suen H, Kwan Y, Bebawy M: Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma. Neoplasia. 2016 Jan;18(1):25-32.
PubMed
Gattei V, Godeas C, Degan M, Rossi FM, Aldinucci D, Pinto A: Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. Br J Haematol. 1999 Jan;104(1):152-62.
PubMed
Variant
100 tests
PO-814-T100
In stock
Variant
0.1 mg
11-261-C100
In stock

Related products

-134%
CloneMOPC-21
Reg. statusRUO
ApplicationFC, negative control
0.1 mg